Climate Change Data

Environmental Metrics

ESG Focus Areas

• Our people
• Our partners
• Our patients
• Our social impact

Environmental Achievements

• Replaced existing lighting with energy-efficient LED lighting
• Installed light movement sensors in car parks to limit energy consumption
• Replaced critical systems, such as chillers, with more efficient equipment to reduce overall energy consumption in our Chippenham site

Social Achievements

• Launched a new Charitable Support Policy which outlines our approach to matched fundraising and local volunteering
• Supported a charity bike ride with 30 employees participating, raising £21,755 for Asthma UK and £1,531 for charities in Germany and Switzerland
• Collaborated academically with local universities and our science, technology, engineering and maths (STEM) group participation

Governance Achievements

• Complied fully with the applicable version (2016) of the UK Corporate Governance Code
• Welcomed Anne Whitaker as a new Independent Non-Executive Director
• Appointed Paul Fry as Chief Financial Officer

Climate Goals & Targets

Environmental Challenges

• Brexit uncertainty
• Supply chain disruption
• Adverse regulatory changes
• Failure or delay in partnering VR647
• Partner failure
• Failure to launch VR315 in a competitive timeframe
• Failure or delay in achieving development milestones
• Failure to effectively scale up the manufacture of the Group’s nebulised platforms for partnering
• Failure to attract or retain talent/key personnel
• Changes in the regulatory, operating or pricing environment
• Failure to protect intellectual property

Mitigation Strategies

• Partners have reviewed stock levels, increased stock levels where deemed appropriate, reviewed raw material inventory levels, built stocks where appropriate, engaged third-party logistics providers, reviewed alternative routings, developed contingency plans, undertaken training of internal supply chain staff, implemented provision for flutiform® release testing in the EU
• Established a legal entity within the EU, appointed a new EU notified body, established a capability to perform EU release testing post-Brexit, assessed and actioned resource and training requirements
• Strong working relationships with suppliers, established due diligence processes, put in place appropriate systems to provide an early warning of potential issues, established contingency arrangements, maintained appropriate levels of safety stock, undertaken supply chain mapping, established additional sources of supply where economically feasible
• Acquired, developed and progressed VR647 based on experience and knowledge of the respiratory market, dedicated experienced personnel responsible for marketing assets and negotiating with potential partners, executing a communication strategy
• Broad range of partners, all collaborations performed under suitable legal agreements, joint steering committees established, regular operational meetings to review demand forecasts, regular dialogue with existing and potential new partners
• Joint clinical team to oversee the conduct of the study, clinical trial results and resubmission to the FDA expected later in 2019
• Established governance process to oversee development programmes, work closely with expert regulatory advisors, conduct clinical trials in accordance with prevailing practice and statutory/regulatory requirements, work with a network of experienced consultants and contractors, implemented Operational Excellence initiatives
• Retention scheme for key employees, transition team in place, plans to increase resources in the UK, outsourced manufacturing partner selected, transition of knowledge to the supplier ongoing
• Career development and talent management programmes, invest in ongoing training and development, succession plans for key roles, market-competitive reward packages, retention scheme for key Gauting site employees, transition team in place, plans to increase resources at the Group’s UK sites
• Work closely with expert regulatory advisors, work with a number of blue-chip pharmaceutical partners, investment in generic products
• Dedicated internal resource, supplemented with external expertise, files for and prosecutes patents, takes steps to enforce these rights, monitors third-party rights

Supply Chain Management

Climate-Related Risks & Opportunities

Environmental Metrics

ESG Focus Areas

• Environment
• Social
• Governance

Environmental Achievements

• Renegotiated electrical utility contracts for main UK sites to 100% renewable sources in 2019.
• Renewed lighting with low-energy LED.
• Chippenham site has a solar array offsetting site utility costs.

Social Achievements

• Ran an internal mental health awareness campaign during COVID-19 pandemic.
• Created a wellbeing hub on the intranet with mental health resources.
• Working towards ISO45001 Health & Safety certification.

Governance Achievements

• Launched a new social intranet, myVectura, for open communication.
• 93% positive response to COVID communications in Employee Pulse survey.
• Implemented new procedures to support Whistleblowing Policy.

Climate Goals & Targets

Environmental Challenges

• Reducing carbon footprint and tackling climate change.
• Improving supplier performance regarding environmental impact.
• Establishing baseline D&I data and setting inclusivity agenda.

Mitigation Strategies

• Established a sustainability taskforce to accelerate ambition to meet Paris Accord commitments.
• Developing an energy efficiency/carbon reduction programme for new Inhalation Centre of Excellence.
• Developing a formal supplier code of conduct.
• Establishing a D&I Committee to set inclusivity agenda and KPIs.

Supply Chain Management

Responsible Procurement

• Improvement initiative with CMOs to reduce environmental impact of suppliers’ activities.
• Publishing a formal supplier code of conduct in 2021.

Climate-Related Risks & Opportunities

Awards & Recognition

• Runner Up in the Employee Wellbeing category of the COVID Comms Awards by Corporate Comms Magazine